IBD in Clinical Practice: Diagnosis and Medical Treatment

Inflammatory Bowel Diseases in Clinical Practice: An Interactive Tutorial for Patient Management
1 AMA PRA Category 1 Credit(s)
Launch Date:
December 02, 2014
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

physicians, gastroenterologists

Relevant Terms:

inflammatory bowel diseases; Crohn's disease; ulcerative colitis

Hans Herfarth, MD, PhD

Hans Herfarth, MD, PhD
Professor of Medicine
University of North Carolina
Chapel Hill, NC

Hans Herfarth, MD, PhD, is Professor of Medicine at the University of North Carolina. His main interest is clinical IBD studies. Dr. Herfarth is the author of more than 190 journal articles, book chapters and reviews related to IBD. He is on the editorial board of Inflammatory Bowel Diseases and is the chairman of the Clinical Research Alliance of the Crohn’s and Colitis Foundation of America (CCFA).

Miguel Regueiro, MD

Miguel Regueiro, MD
Professor of Medicine
Co-Director of the Inflammatory Bowel Disease Center

University of Pittsburgh Medical Center
Pittsburgh, PA

Miguel Regueiro earned his bachelor’s degree at the University of Pennsylvania, his medical degree at Hahnemann University and completed his internal medicine internship and residency, and clinical and research fellowship training in gastroenterology at Harvard Medical School’s Beth Israel Hospital.

Dr. Regueiro is Professor of Medicine at the University of Pittsburgh School of Medicine, Head of the Clinical Inflammatory Bowel Disease Program, and Co-Director of the Inflammatory Bowel Disease Center at the University of Pittsburgh Medical Center. He is also the Associate Chief for Education and former Director of the Gastroenterology, Hepatology, and Nutrition Fellowship Training Program at the University of Pittsburgh.

Dr. Regueiro’s main clinical and research interest is inflammatory bowel disease (IBD), with a focus on Crohn’s disease and ulcerative colitis. Dr. Regueiro has published extensively on the prevention and management of postoperative Crohn’s disease and genotype-phenotype correlations in IBD. He is the principal investigator on several multi-center, international research trials and conducts clinical research that defines the natural course and phenotypes of inflammatory bowel disease. Dr. Regueiro has developed a multidisciplinary IBD Center that operates as a state-of-the-art clinic for patients with Crohn’s disease and ulcerative colitis.

Dr. Regueiro has received several honors and holds membership in professional and scientific societies, including the Alpha Omega Alpha Honor Society, the Joan Komblum Memorial Prize for Excellence in Internal Medicine, the Clinical Investigator Training Award from Harvard/MIT Health Sciences, the Crohn's & Colitis Foundation of America Physician of the Year, the National Research Excellence in GI disease award, numerous fellowship teaching awards, and American Gastroenterology Association and American College of Gastroenterology Fellowships. He is also a member and fellow of the American Gastroenterological Association, the American College of Gastroenterology and the American College of Physicians. He is a member of the Crohn’s & Colitis Foundation of America (CCFA) and Co-Chair of CCFA’s professional education committee. In addition, Dr. Regueiro has been an invited lecturer and keynote speaker for national and international seminars and has published many articles, reviews and abstracts in peer-reviewed gastroenterology journals.
1. Describe indications for and interpretation of diagnostic testing in inflammatory bowel diseases
2. Apply principles of therapeutic management according to clinical symptoms, duration, and severity of disease

New IBD medications, including biosimilars, have been approved since the creation of this resource. A revised version of the program will be developed once this version expires. View a listing of recently approved IBD medications: http://www.ccfa.org/assets/pdfs/recently-approved-treatments.pdf
Reading Resources:
  1. Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014 Sep 5. [Epub ahead of print]. doi: 10.1016/j.mayocp.2014.07.002.
  2. Jones J, Peña-Sánchez JN. Who should receive biologic therapy for IBD?: The rationale for the application of a personalized approach. Gastroenterol Clin North Am. 2014;43(3):425-440.
  3. Levesque BG, Sandborn WJ, Ruel J, Feagan BG, Sands BE, Colombel JF. Converging goals of treatment for inflammatory bowel disease, from clinical trials and practice. Gastroenterology. 2014 Aug 12. [Epub ahead of print]. doi: 10.1053/j.gastro.2014.08.003.
  4. Mosli MH, Sandborn WJ, Kim RB, Khanna R, Al-Judaibi B, Feagan BG. Toward a personalized medicine approach to the management of inflammatory bowel disease. Am J Gastroenterol. 2014;109(7):994-1004.
Hans Herfarth, MD, PhD, has affiliations with Celltrion, Janssen, Pfizer (Consultant).
Miguel Regueiro, MD, has affiliations with AbbVie, Janssen, Takeda, UCB (Consultant).
Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Pittsburgh School of Medicine and Crohn's & Colitis Foundation of America. The University of Pittsburgh School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Pittsburgh School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Each physician should only claim credit commensurate with the extent of their participation in the activity.
Other health care professionals are awarded .10 continuing education units (CEUs), which are equal to 1.0 contact hours. Faculty for this activity have been requested to identify significant financial or other relationships with manufacturer(s) of any commercial product(s) or with provider(s) of any commercial service(s) which might affect the balance of their presentation.
Estimated time to complete:  60 minutes
Medium: Internet

There is no fee for this educational activity.

This activity is jointly provided by The University of Pittsburgh School of Medicine and the Crohn's & Colitis Foundation of America. This activity is supported by independent educational grants from Actavis, Prometheus, Takeda and UCB.
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1 AMA PRA Category 1 Credits™.
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Physicians who successfully complete the post-test and evaluation will receive AMA credit. You must score a 65% or higher on the post-test to receive credit for this activity. You will have three attempts to take the post-test.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above

For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above